Loading...
•
Oct 02, 2021
USANA Q3 2021 Earnings Report
Net sales and diluted EPS decreased due to challenging operating environment and difficult prior-year comparison.
Key Takeaways
USANA Health Sciences reported third quarter results modestly ahead of preliminary outlook. Net sales were $274.4 million, a decrease compared to $298.5 million in the prior year. Diluted EPS were $1.36, down from $1.44 in the third quarter of 2020. The company reiterated its fiscal 2021 net sales and diluted EPS outlook and expects to generate approximately $130 million of free cash flow in fiscal 2021.
Third quarter net sales were $274.4 million, compared to $298.5 million in the prior year.
Third quarter diluted EPS was $1.36, versus $1.44 in the third quarter of 2020.
Company ended the quarter with $249 million in cash and cash equivalents and no debt after repurchasing 523,000 shares for $50 million.
The company reiterated its net sales and earnings per share outlook for fiscal year 2021.
Revenue by Geographic Location
Forward Guidance
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2021, which was provided on September 16, 2021. Fiscal Year 2021 Outlook Range Consolidated Net Sales $1.18 - $1.20 billion Diluted EPS $5.80 - $6.00
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...